Bloomberg News

Bayer’s Xarelto Backed in Final Stroke Guidance From U.K.’s NICE

May 22, 2012

The U.K.’s National Institute for Health and Clinical Excellence published final guidance recommending Bayer AG (BAYN)’s Xarelto blood-thinner as a cost- effective way to prevent strokes in people with an irregular heartbeat known as atrial fibrillation.

Deciding whether to start treatment with the drug should be made after the patient and physician have discussed Xarelto’s risks and benefits compared with warfarin, an older treatment, the health-cost agency, known as NICE, said today in an e-mailed statement.

To contact the reporter on this story: Kristen Hallam in London at khallam@bloomberg.net

To contact the editor responsible for this story: Kristen Hallam at khallam@bloomberg.net


American Apparel's Future
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus